Nothing said here yet.
to join the conversation.
| Allan JonathanGENERAL COUNSEL & CORP SEC | Sell | 627 | $16.5K | Fri, Oct 2 |
| Ticho BarryCHIEF MEDICAL OFFICER | Sell | 1,051 | $27.5K | Thu, Oct 1 |
| Ticho BarryCHIEF MEDICAL OFFICER | Sell | 3,945 | $120.4K | Tue, Sep 1 |
| Ticho BarryCHIEF MEDICAL OFFICER | Sell | 1,600 | $49.7K | Tue, Sep 1 |
| Kaye Edward M. MDDirector | Sell | 11,930 | $381.8K | Tue, Aug 18 |
| Ticho BarryCHIEF MEDICAL OFFICER | Sell | 4,525 | $144.8K | Tue, Aug 18 |
| Allan JonathanGENERAL COUNSEL & CORP SEC | Sell | 2,716 | $86.9K | Tue, Aug 18 |
| Kaye Edward M. MDDirector | Sell | 637 | $20.7K | Tue, Aug 18 |
| Ticho BarryCHIEF MEDICAL OFFICER | Sell | 242 | $7.9K | Tue, Aug 18 |
| Allan JonathanGENERAL COUNSEL & CORP SEC | Sell | 145 | $4.7K | Tue, Aug 18 |
Stoke Therapeutics slipped 0.2% to US$26.29 after posting Q3 2026 numbers, a muted reaction for a biotech still deep in the development stage.
Dravet syndrome trial enrollment exceeded targets with zero discontinuations.
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulatory submission later that year and a…
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -22.73% and +35.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics recently announced that it will present first-in-human translational data for its investigational ADOA therapy STK-002 at the AAO 2026 meeting, while continuing dose escalation in the Phase 1 OSPREY trial across eight active European sites.
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure…